Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review

References

• VisserSNLesesneCAPerouRNational estimates and factors associated with medication treatment for childhood attention-deficit/hyperactivity disorderPediatrics2007119Suppl 1S99S10617272592
   PubMed Web of Science ®Google Scholar
• PliszkaSPractice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorderJ Am Acad Child Adolesc Psychiatry200746789492117581453
   PubMed Web of Science ®Google Scholar
• BrownRTAmlerRWFreemanWSTreatment of attention-deficit/hyperactivity disorder: overview of the evidencePediatrics20051156e749e75715930203
   PubMed Web of Science ®Google Scholar
• WongDTThrelkeldPGBestKLBymasterFPA new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brainJ Pharmacol Exp Ther1982222161656123593
   PubMed Web of Science ®Google Scholar
• Bolden-WatsonCRichelsonEBlockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomesLife Sci19935212102310298445992
   PubMed Web of Science ®Google Scholar
• BymasterFPKatnerJSNelsonDLAtomoxetine increases extra-cellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorderNeuropsychopharmacology200227569971112431845
   PubMed Web of Science ®Google Scholar
• SwansonCJPerryKWKoch-KruegerSKatnerJSvenssonKABymasterFPEffect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the ratNeuropharmacology200650675576016427661
   PubMed Web of Science ®Google Scholar
• WitcherJWLongASmithBAtomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorderJ Child Adolesc Psychopharmacol2003131536312804126
   PubMed Web of Science ®Google Scholar
• SauerJMRingBJWitcherJWClinical pharmacokinetics of atomoxetineClin Pharmacokinet200544657159015910008
   PubMed Web of Science ®Google Scholar
• CormanSLFedutesBACulleyCMAtomoxetine: the first non-stimulant for the management of attention-deficit/hyperactivity disorderAm J Health Syst Pharm200461222391239915581262
   PubMed Web of Science ®Google Scholar
• RingBJGillespieJSEcksteinJAWrightonSAIdentification of the human cytochromes P450 responsible for atomoxetine metabolismDrug Metab Dispos200230331932311854152
   PubMed Web of Science ®Google Scholar
• SauerJMPonslerGDMattiuzELDisposition and metabolic fate of atomoxetine hydrochloride: The role of CYP2D6 in human disposition and metabolismDrug Metab Dispos2003319810712485958
   PubMed Web of Science ®Google Scholar
• MichelsonDAdlerLAmsterdamJAddition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled studyJ Clin Psychiatry200768458258717474814
   PubMed Web of Science ®Google Scholar
• ChalonSADesagerJPDesanteKAEffect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolitesClin Pharmacol Ther200373317819112621383
   PubMed Web of Science ®Google Scholar
• SpencerTBiedermanJHeiligensteinJAn Open-Label, Dose-Ranging Study of Atomoxetine in Children with Attention Deficit Hyperactivity DisorderJ Child Adolesc Psychopharmacol200111325126511642475
   PubMed Web of Science ®Google Scholar
• MichelsonDFariesDWernickeJAtomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose-response studyPediatrics20011085
   Web of Science ®Google Scholar
• WeissMTannockRKratochvilCA randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHDJ Am Acad Child Adolesc Psychiatry200544764765515968233
   PubMed Web of Science ®Google Scholar
• ChengJYChenRYKoJSNgEMEfficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysisPsychopharmacology (Berl)2007194219720917572882
   PubMed Web of Science ®Google Scholar
• KratochvilCJMiltonDRVaughanBSGreenhillLLAcute atomoxetine treatment of younger and older children with ADHD: A meta-analysis of tolerability and efficacyChild Adolesc Psychiatry Ment Health2008212518793405
   PubMedGoogle Scholar
• FaraoneSVBiedermanJSpencerTJAleardiMComparing the efficacy of medications for ADHD using meta-analysisMed Gen Med2006844
   PubMedGoogle Scholar
• KemnerJEStarrHLCicconePEHooper-WoodCGCrockettRSOutcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective studyAdv Ther200522549851216418159
   PubMed Web of Science ®Google Scholar
• WigalSBMcGoughJJMcCrackenJTA laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorderJ Atten Disord20059127528916371674
   PubMedGoogle Scholar
• KratochvilCJHeiligensteinJHDittmanRAtomoxetine and methylphenidate treatment in children with ADHD: A prospective, randomized, open-label trialJ Am Acad Child Adolesc Psychiatry200241777678412108801
   PubMed Web of Science ®Google Scholar
• WilensTENewcornJHKratochvilCJLong-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorderJ Pediatr2006149111211916860138
   PubMed Web of Science ®Google Scholar
• MichelsonDAllenAJBusnerJOnce-Daily Atomoxetine Treatment for Children and Adolescents with Attention Deficit Hyperactivity Disorder: A Randomized, Placebo-Controlled StudyAm J Psychiatry2002159111896190112411225
   PubMed Web of Science ®Google Scholar
• KelseyDKSumnerCRCasatCDOnce-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trialPediatrics20041141e1e815231966
   PubMed Web of Science ®Google Scholar
• NewcornJHKratochvilCJAllenAJAtomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential responseAm J Psychiatry2008165672173018281409
   PubMed Web of Science ®Google Scholar
• QuintanaHCherlinEADuesenbergDATransition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder – a preliminary tolerability and efficacy studyClin Ther20072961168117717692731
   PubMed Web of Science ®Google Scholar
• HammernessPMickEDoyleRAtomoxetine in children with attention deficit hyperactivity disorder (ADHD) with prior poor response to stimulant therapy: a prospective open label studyEur Child Adolesc Psychiatry2009 in revision
   Web of Science ®Google Scholar
• KratochvilCJMichelsonDNewcornJHHigh-dose atomoxetine treatment of ADHD in youths with limited response to standard dosesJ Am Acad Child Adolesc Psychiatry20074691128113717712236
   PubMed Web of Science ®Google Scholar
• SaferDJZitoJMDosReisSConcomitant psychotropic medication for youthsAm J Psychiatry2003160343844912611822
   PubMed Web of Science ®Google Scholar
• CarlsonGADunnDKelseyDA pilot study for augmenting atomoxetine with methylphenidate: safety of concomitant therapy in children with attention-deficit/hyperactivity disorderChild Adolesc Psychiatry Ment Health2007111017897473
   PubMedGoogle Scholar
• WilensTHammernessPUtzingerLAn open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: I. effectivenessJ Child Adolesc PsychopharmacolIn press
   Web of Science ®Google Scholar
• KratochvilCWilensTGreenhillLEffects of long-term atomoxetine treatment for young children with Attention-deficit/hyperactive disorderJ Am Acad Child Adolesc Psychiatry200645891992716865034
   PubMed Web of Science ®Google Scholar
• SpencerTJKratochvilCJSangalRBEffects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatmentJ Child Adolesc Psychopharmacol200717568969917979588
   PubMed Web of Science ®Google Scholar
• BakkenRJPaczkowskiMKramerHPEffects of atomoxetine on attention-deficit/hyperactivity disorder in clinical pediatric treatment settings: a naturalistic studyCurr Med Res Opin200824244946018179733
   PubMed Web of Science ®Google Scholar
• MichelsonDBuitelaarJKDanckaertsMRelapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled studyJ Am Acad Child Adolesc Psychiatry200443789690415213591
   PubMed Web of Science ®Google Scholar
• MichelsonDTreatment of ADHD: beyond stimulants. Presented at the 15th European Neuropsychopharmacology Congress, Barcelona, SpainEur Neuropsychopharmacol200212Suppl 3S77S45712418468
   PubMedGoogle Scholar
• BuitelaarJKMichelsonDDanckaertsMA randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 yearBiol Psychiatry200761569469916893523
   PubMed Web of Science ®Google Scholar
• BiedermanJSpencerTJNewcornJHEffect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial dataPsychopharmacology (Berl)20071901314117093981
   PubMed Web of Science ®Google Scholar
• NewcornJHSpencerTJBiedermanJMiltonDRMichelsonDAtomoxetine Treatment in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant DisorderJ Am Acad Child Adolesc Psychiatry200544324024815725968
   PubMed Web of Science ®Google Scholar
• HazellPZhangSWolanczykTComorbid oppositional defiant disorder and the risk of relapse during 9 months of atomoxetine treatment for attention-deficit/hyperactivity disorderEur Child Adolesc Psychiatry200615210511016523251
   PubMed Web of Science ®Google Scholar
• SpencerTHeiligensteinJHBiedermanJResults from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorderJ Clin Psychiatry200263121140114712523874
   PubMed Web of Science ®Google Scholar
• KaplanSHeiligensteinJWestSEfficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorderJ Atten Disord200482455215801334
   PubMedGoogle Scholar
• BangsMEHazellPDanckaertsMAtomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorderPediatrics20081212e314e32018245404
   PubMed Web of Science ®Google Scholar
• ArnoldPSicardTBurroughsERichterMKennedyJGlutamate transporter gene SLC1A1 associated with obsessive-oompulsive disorderArch Gen Psychiatry200663771772016818860
   PubMed Web of Science ®Google Scholar
• TroostPWSteenhuisMPTuynman-QuaHGAtomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot studyJ Child Adolesc Psychopharmacol200616561161917069549
   PubMed Web of Science ®Google Scholar
• PoseyDEricksonCStiglerKAMcDougleCThe use of selective serotonin reuptake inhibitors in autism and related disordersJ Child Adolesc Psychopharmacol2006161218118616553521
   PubMed Web of Science ®Google Scholar
• AllenAJKurlanRGilbertDLAtomoxetine treatment in children and adolescents with ADHD and comorbid tic disordersNeurology2005651941194916380617
   PubMed Web of Science ®Google Scholar
• GellerDDonnellyCLopezFAtomoxetine treatment for pediatric patients with ADHD and comorbid anxietyJ Am Acad Child Adolesc Psychiatry200746911
   Web of Science ®Google Scholar
• AbikoffHMcGoughJVitielloBSequential pharmacotherapy for children with comorbid Attention-Deficit/Hyperactivity and anxiety disordersJ Am Acad Child Adolesc Psychiatry200544541842715843763
   PubMed Web of Science ®Google Scholar
• BangsMEEmslieGJSpencerTJEfficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depressionJ Child Adolesc Psychopharmacol200717440742017822337
   PubMed Web of Science ®Google Scholar
• KratochvilCJNewcornJHArnoldLEAtomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptomsJ Am Acad Child Adolesc Psychiatry200544991592416113620
   PubMed Web of Science ®Google Scholar
• HahMChangKAtomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents with bipolar disordersJ Child Adolesc Psychopharmacol2005156996100416379520
   PubMed Web of Science ®Google Scholar
• GreenhillLLNewcornJHGaoHFeldmanPDEffect of two different methods of initiating atomoxetine on the adverse event profile of atomoxetineJ Am Acad Child Adolesc Psychiatry200746556657217450047
   PubMed Web of Science ®Google Scholar
• PolzerJBangsMEZhangSMeta-analysis of aggression or hostility events in randomized, controlled clinical trials of atomoxetine for ADHDBiol Psychiatry200761571371916996485
   PubMed Web of Science ®Google Scholar
• LimJRFaughtPRChalasaniNPMollestonJPSevere liver injury after initiating therapy with atomoxetine in two childrenJ Pediatr2006148683183416769398
   PubMed Web of Science ®Google Scholar
• PerrinJMFriedmanRAKnilansTKCardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorderPediatrics2008122245145318676566
   PubMed Web of Science ®Google Scholar
• Association A. American Academy of Pediatrics/American Heart Association clarification of statement on cardiovascular evaluation and monitoring of children and adolscents with heart disease receiving medications for ADHD. May 16, 2008
   Google Scholar
• WernickeJFHoldridgeKCJinLSeizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetineDev Med Child Neurol200749749850217593120
   PubMed Web of Science ®Google Scholar
• StojanovskiSDRobinsonRFBakerSDCasavantMJHayesJRNahataMCChildren and adolescent exposures to atomoxetine hydrochloride reported to a poison control centerClin Toxicol (Phila)200644324324716749540
   PubMed Web of Science ®Google Scholar
• SpillerHALintnerCPWinterMLAtomoxetine ingestions in children: a report from poison centersAnn Pharmacother20053961045104815870137
   PubMed Web of Science ®Google Scholar
• LovecchioFKashaniJIsolated atomoxetine (Strattera) ingestions commonly result in toxicityJ Emerg Med200631326726816982359
   PubMed Web of Science ®Google Scholar
• ForresterMBAdult atomoxetine ingestions reported to Texas Poison Control Centers, 2003–2005Ann Pharmacother200640122136214117090726
   PubMed Web of Science ®Google Scholar
• KashaniJRuhaAMIsolated atomoxetine overdose resulting in seizureJ Emerg Med200732217517817307628
   PubMed Web of Science ®Google Scholar
• PárragaHPárragaMHarrisDTic exacerbation and precipitation during atomoxetine treatment in two children with attention-deficit hyperactivity disorderInt J Psychiatry Med200737441542418441629
   PubMed Web of Science ®Google Scholar
• BondGRGarroACGilbertDLDyskinesias associated with atomoxetine in combination with other psychoactive drugsClin Toxicol (Phila)200745218218517364639
   PubMed Web of Science ®Google Scholar
• AllenAJMichelsonDDrug development process for a product with a primary pediatric indicationJ Clin Psychiatry200263 Suppl 12444912562061
   PubMed Web of Science ®Google Scholar